Gibson, A.J.W.; Box, A.; Cheung, W.Y.; Dean, M.L.; Elegbede, A.A.; Hao, D.; Pabani, A.; Sangha, R.; Bebb, D.G.
Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. Curr. Oncol. 2022, 29, 1967-1982.
https://doi.org/10.3390/curroncol29030160
AMA Style
Gibson AJW, Box A, Cheung WY, Dean ML, Elegbede AA, Hao D, Pabani A, Sangha R, Bebb DG.
Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. Current Oncology. 2022; 29(3):1967-1982.
https://doi.org/10.3390/curroncol29030160
Chicago/Turabian Style
Gibson, Amanda J. W., Adrian Box, Winson Y. Cheung, Michelle L. Dean, Anifat A. Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha, and Dafydd Gwyn Bebb.
2022. "Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort" Current Oncology 29, no. 3: 1967-1982.
https://doi.org/10.3390/curroncol29030160
APA Style
Gibson, A. J. W., Box, A., Cheung, W. Y., Dean, M. L., Elegbede, A. A., Hao, D., Pabani, A., Sangha, R., & Bebb, D. G.
(2022). Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. Current Oncology, 29(3), 1967-1982.
https://doi.org/10.3390/curroncol29030160
